For postmenopausal women with HR+ breast cancer
If you've been diagnosed with hormone receptor-positive (HR+) early breast cancer, you and your doctor may be discussing treatment options for reducing the risk of breast cancer recurrence.
ARIMIDEX is a prescription medicine approved as an adjuvant treatment for postmenopausal women with hormone receptor-positive early breast cancer. ARIMIDEX is also approved for the initial treatment of postmenopausal women with hormone-receptor positive or hormone receptor-unknown locally advanced or metastatic breast cancer and for the treatment of postmenopausal women with advanced breast cancer that has progressed following treatment with tamoxifen. ARIMIDEX 1 mg is a hormonal treatment that helps fight breast cancer by lowering the amount of the hormone estrogen in the body.